Foley Hoag Sample Contracts

Share Cite Term
Link

Embed (HTML)
Minerva Neurosciences, Inc. – Sublease Agreement (October 6th, 2017)

THIS SUBLEASE AGREEMENT (this Sublease), dated as of October 2, 2017, is entered into by and between Profitect, Inc., a Delaware corporation, (Sublandlord), and Minerva Neurosciences, Inc., a Delaware corporation, (Subtenant).

Astro-Med, Inc. – ASSET PURCHASE AND LICENSE AGREEMENT BY AND BETWEEN ASTRONOVA, INC. AND HONEYWELL INTERNATIONAL INC. SEPTEMBER 28, 2017 License Agreement No. 2017-8072 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. TRIPLE ASTERISKS [***] DENOTE OMISSIONS. (October 4th, 2017)

THIS ASSET PURCHASE AND LICENSE AGREEMENT (this Agreement) is made this 28th day of September 2017, by and between AstroNova, Inc., a Rhode Island corporation, (Purchaser), and Honeywell International Inc., a Delaware corporation (Seller and together with the Purchaser, the Parties and each a Party).

Exa Corporation – AGREEMENT AND PLAN OF MERGER Among DASSAULT SYSTEMES SIMULIA CORP., 3DS ACQUISITION 3 CORP. And EXA CORPORATION Dated as of September 27, 2017 (September 28th, 2017)

THIS AGREEMENT AND PLAN OF MERGER (this Agreement) is made and entered into as of September 27, 2017 (the Agreement Date), by and among Dassault Systemes Simulia Corp., a Rhode Island corporation (Parent), 3DS Acquisition 3 Corp., a Delaware corporation and a direct wholly owned subsidiary of Parent (Purchaser), and Exa Corporation, a Delaware corporation (the Company). Each of Parent, Purchaser and the Company are referred to herein as a Party and together as Parties.

STOCK PURCHASE AGREEMENT BY AND AMONG LOGMEIN KFT., LOGMEIN, INC., NANOREP TECHNOLOGIES LTD., THE SHAREHOLDERS OF NANOREP TECHNOLOGIES LTD. AND SHAREHOLDER REPRESENTATIVE SERVICES LLC IN ITS CAPACITY AS REPRESENTATIVE July 31, 2017 (August 1st, 2017)

This STOCK PURCHASE AGREEMENT (this Agreement) is made as of July 31, 2017, by and among LogMeIn Kft., a Hungarian company (Buyer), LogMeIn, Inc., a Delaware corporation (Parent), Nanorep Technologies Ltd., an Israeli company (the Company), the persons and entities set forth on Exhibit A hereto (collectively, the Shareholders), and Shareholder Representative Services LLC, a Colorado limited liability company solely in its capacity as representative of the Shareholders (the Representative). Capitalized terms used and not otherwise defined herein have the meanings set forth in ARTICLE XII below.

AGREEMENT AND PLAN OF MERGER Among INVITAE CORPORATION, BUENO MERGER SUB, INC., GOOD START GENETICS, INC., THE NOTEHOLDERS THE MANAGEMENT CARVEOUT PLAN PARTICIPANTS and ORBIMED PRIVATE INVESTMENTS III, LP, as Holders Representative July 31, 2017 (August 1st, 2017)

THIS AGREEMENT AND PLAN OF MERGER (this Agreement), is dated as of July 31, 2017 (the Signing Date), by and among INVITAE CORPORATION, a Delaware corporation (Parent), BUENO MERGER SUB, INC., a Delaware corporation (Merger Sub), GOOD START GENETICS, INC., a Delaware corporation (the Company), the Noteholders, the Management Carveout Plan Participants and OrbiMed Private Investments III, LP, as representative of the Holders and Management Carveout Plan Participants (as more thoroughly defined in Section 8.5, Holders Representative). Each of Parent, Merger Sub, the Company, the Noteholders, the Management Carveout Plan Participants and Holders Representative may be individually referred to herein as a Party and collectively referred to herein as the Parties. Capitalized terms used herein have the meanings ascribed thereto in Article 1 or elsewhere in this Agreement as identified in Article 1.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION Among OPEXA THERAPEUTICS, INC. OPEXA MERGER SUB, INC., and ACER THERAPEUTICS INC. Dated as of June 30, 2017 (July 3rd, 2017)

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this Agreement) is made and entered into as of June 30, 2017, by and among Opexa Therapeutics, Inc., a Texas corporation (Opexa), Opexa Merger Sub, Inc., a Delaware corporation (Merger Sub), and Acer Therapeutics Inc., a Delaware corporation (Acer). Certain capitalized terms used in this Agreement are defined in Exhibit A.

Fifth Amended and Restated Investors' Rights Agreement (June 23rd, 2017)

THIS FIFTH AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT ("Agreement") is made as of the 22nd day of June, 2017, by and between Proteon Therapeutics, Inc., a Delaware corporation (the "Company"), and each of the investors listed on Schedule A hereto, together with any persons or entities that become parties hereto pursuant to Section 3.9 (the "Investors").

Fifth Amended and Restated Investors' Rights Agreement (June 23rd, 2017)

THIS FIFTH AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT ("Agreement") is made as of the 22nd day of June, 2017, by and between Proteon Therapeutics, Inc., a Delaware corporation (the "Company"), and each of the investors listed on Schedule A hereto, together with any persons or entities that become parties hereto pursuant to Section 3.9 (the "Investors").

Securities Purchase Agreement (June 23rd, 2017)

SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of June 22, 2017, by and among Proteon Therapeutics, Inc., a Delaware corporation, with headquarters located at 200 West Street, Waltham, MA 02451 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyers").

Securities Purchase Agreement (June 23rd, 2017)

SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of June 22, 2017, by and among Proteon Therapeutics, Inc., a Delaware corporation, with headquarters located at 200 West Street, Waltham, MA 02451 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyers").

Kvh Industries – KVH INDUSTRIES, INC. INDENTURE Dated as of , 20 Trustee (June 21st, 2017)

Indenture dated as of , 20 between KVH Industries, Inc., a Delaware corporation (the Company), and [ ] (the Trustee). Each party agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders of the Securities issued under this Indenture.

Seventh Amendment to Lease (June 9th, 2017)

THIS SEVENTH AMENDMENT TO LEASE (this Amendment) is entered into as of this 30th day of May, 2017 (the Seventh Amendment Execution Date), by and between BMR-34790 ARDENTECH COURT LP, a Delaware limited partnership (Landlord, formerly known as BMR-34790 Ardentech Court LLC), and ZP OPCO, INC., a Delaware corporation (Tenant, formerly known as Zosano Pharma, Inc. and, previously, The Macroflux Corporation).

Astro-Med, Inc. – Astronova, Inc. Stock Repurchase Agreement (May 5th, 2017)

This Stock Repurchase Agreement (this Agreement) is made as of May 1, 2017, by and among AstroNova, Inc., a Rhode Island corporation (the Company), and the trust established by Albert W. Ondis by Declaration of Trust dated December 4, 2003, as amended (the Selling Shareholder).

Ecology and Environment, Inc. – Settlement Agreement (April 25th, 2017)

This SETTLEMENT AGREEMENT (this Agreement) is made and entered into as of April 19, 2017, among Ecology and Environment, Inc., a New York corporation (the Company), on the one hand, and Mill Road Capital II, L.P., a Delaware limited liability partnership, Mill Road Capital II GP LLC, a Delaware limited liability company, Mill Road Capital Management LLC, a Delaware limited liability company, and Justin C. Jacobs (collectively, Mill Road), on the other hand. The Company and Mill Road are each referred to herein as a Party and collectively, as the Parties.

SECURITIES PURCHASE AGREEMENT by and Among NOODLES & COMPANY and MILL ROAD CAPITAL II, L.P. March 13, 2017 (March 14th, 2017)

SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated March 13, 2017, by and among Noodles & Company, a Delaware corporation (the "Company"), and Mill Road Capital II, L.P., a Delaware limited partnership (the "Purchaser").

PSIVIDA CORP. Common Stock (Par Value $0.001 Per Share) at Market Issuance Sales Agreement (February 8th, 2017)

pSivida Corp., a Delaware corporation (the Company), confirms its agreement (this Agreement), with FBR Capital Markets & Co. (FBR), as follows:

Cellectar Biosciences, Inc. – Underwriting Agreement (November 18th, 2016)

The undersigned, CELLECTAR BIOSCIENCES, INC., a Delaware corporation (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Cellectar Biosciences, Inc., the "Company"), hereby confirms its agreement (this "Agreement") with the several underwriters (such underwriters, including the Representative (as defined below), the "Underwriters" and each an "Underwriter") named in Schedule I hereto for which LADENBURG THALMANN & CO. INC. is acting as representative to the several Underwriters (the "Representative" and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.

Cellectar Biosciences, Inc. – SERIES C-2016 COMMON STOCK PURCHASE WARRANT Cellectar Biosciences, Inc. (November 18th, 2016)

THIS SERIES C-2016 COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, _____________ or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ___, 2016 (the "Initial Exercise Date") and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the "Termination Date") but not thereafter, to subscribe for and purchase from Cellectar Biosciences, Inc., a Delaware corporation (the "Company"), up to ______ shares (as subject to adjustment hereunder, the "Warrant Shares") of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Cellectar Biosciences, Inc. – Cellectar Biosciences, Inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES a CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW (November 18th, 2016)
Vermont Pure Holdings, Ltd. – Employment Agreement (November 2nd, 2016)

This EMPLOYMENT AGREEMENT (this "Agreement") dated as of November 1, 2016 (the "Effective Date"), is by and between CRYSTAL ROCK HOLDINGS, INC., a Delaware corporation (together with any subsidiaries, the "Company"), and PETER K. BAKER (the "Executive").

Vermont Pure Holdings, Ltd. – Employment Agreement (November 2nd, 2016)

This EMPLOYMENT AGREEMENT (this "Agreement") dated as of November 1, 2016 (the "Effective Date"), is by and between CRYSTAL ROCK HOLDINGS, INC., a Delaware corporation (together with any subsidiaries, the "Company"), and JOHN B. BAKER (the "Executive").

Vermont Pure Holdings, Ltd. – Employment Agreement (November 2nd, 2016)

This EMPLOYMENT AGREEMENT (this "Agreement") dated as of November 1, 2016 (the "Effective Date"), is by and between CRYSTAL ROCK HOLDINGS, INC., a Delaware corporation (together with any subsidiaries, the "Company"), and DAVID JURASEK (the "Executive").

Mill Road Capital II, L.P. – Mill Road Capital II, L.P. (October 28th, 2016)

This letter, including the Exhibits, Schedules and Annexes attached hereto, is collectively referred to as the Notice. The persons Mill Road intends to nominate for election to the Board as Class A Members at the Annual Meeting are Justin Jacobs and Michael El-Hillow (each a Nominee and collectively, the Nominees). Mill Road believes that the shareholders of the Company have fixed the number of directors at seven (7), with two (2) directors allocated as Class A Members and five (5) directors allocated as Class B Members, all of which are scheduled for election at the Annual Meeting. This Notice, in addition to being the notice of nomination required under Section 4 of Article II of the Bylaws, can also be deemed to be a request that the Company name the Nominees in its proxy statement as nominees for election to the Board at the Annual Meeting.

Golub Capital Investment Corp – Golub Capital Investment Corporation as Borrower REVOLVING CREDIT AGREEMENT SUMITOMO MITSUI BANKING CORPORATION as Administrative Agent, Sole Lead Arranger and Sole Manager Date of Credit Agreement: May 17, 2016 Closing Date: May 17, 2016 (September 15th, 2016)

THIS REVOLVING CREDIT AGREEMENT is dated as of May 17, 2016 by and among GOLUB CAPITAL INVESTMENT CORPORATION, a Maryland corporation ("Borrower"), and SUMITOMO MITSUI BANKING CORPORATION, a foreign banking corporation organized under the laws of Japan (in its individual capacity, "SMBC"), as Administrative Agent for the Lenders (as each term is hereinafter defined), and the Lenders.

MASTER ACQUISITION AGREEMENT DATED AS OF September 12, 2016 BY AND AMONG EMC CORPORATION, EMC INTERNATIONAL COMPANY, EMC (BENELUX) B.V. AND OPEN TEXT CORPORATION (September 13th, 2016)

THIS MASTER ACQUISITION AGREEMENT (this "Agreement") is entered into as of September 12, 2016, by and among EMC Corporation, a Massachusetts corporation ("EMC"), EMC International Company, a company organized under the laws of Ireland ("EIC"), EMC (Benelux) B.V., a besloten vennootschap organized under the laws of Netherlands ("EMC Benelux"), and Open Text Corporation, a corporation incorporated under the federal laws of Canada (the "Purchaser"). Certain other capitalized terms used in this Agreement are defined in the appended Exhibit A.

Securities Purchase Agreement (September 9th, 2016)

THIS SECURITIES PURCHASE AGREEMENT (this Agreement), dated as of August 15, 2016, by and among Zosano Pharma Corporation, a Delaware corporation with headquarters located at 34790 Ardentech Court, Freemont, California 94555 (the Company), and each investor identified on the signature pages hereto (individually, an Investor and collectively, the Investors).

Skullcandy Inc. – Skullcandy Enters Into New Merger Agreement With Mill Road Capital; Terminates Incipio Merger Agreement Mill Road Capital Offers Stockholders $6.35 Per Share in Cash (August 24th, 2016)

Park City, Utah and South San Francisco, California, August 24, 2016 Skullcandy, Inc. (Nasdaq: SKUL), which creates world-class audio experiences through its Skullcandy(r) and Astro Gaming(r) brands, today announced the termination of the previously announced merger agreement (the Incipio Merger Agreement) with Incipio, LLC (Incipio), and the entry into a new merger agreement (the Mill Road Merger Agreement) with MRSK Hold Co. and MRSL Merger Co., entities affiliated with Mill Road Capital Management LLC (collectively, Mill Road). Under the terms of the Mill Road Merger Agreement, outstanding shares of common stock of Skullcandy will be exchanged for $6.35 per share in cash at the completion of the merger, or a total of approximately $196.6 million.

Skullcandy Inc. – AGREEMENT AND PLAN OF MERGER by and Among MRSK HOLD CO., MRSL MERGER CO. And SKULLCANDY, INC. Dated as of August 23, 2016 (August 24th, 2016)

THIS AGREEMENT AND PLAN OF MERGER (this Agreement) is made and entered into as of August 23, 2016 by and among MRSK Hold Co., a Delaware corporation (Parent), MRSL Merger Co., a Delaware corporation and a direct wholly owned subsidiary of Parent (Acquisition Sub), and Skullcandy, Inc., a Delaware corporation (the Company).

Confidential Settlement and Release Agreement (August 23rd, 2016)

This confidential settlement and release agreement (Settlement) is entered into and effective as of August 18, 2016 (the Effective Date), by and among:

Securities Purchase Agreement (August 16th, 2016)

THIS SECURITIES PURCHASE AGREEMENT (this Agreement), dated as of August 15, 2016, by and among Zosano Pharma Corporation, a Delaware corporation with headquarters located at 34790 Ardentech Court, Freemont, California 94555 (the Company), and each investor identified on the signature pages hereto (individually, an Investor and collectively, the Investors).

Skullcandy Inc. – August 15, 2016 Members of the Board of Directors of Skullcandy, Inc. C/O Peter J. Solomon Company 1345 Avenue of the Americas, 31st Floor New York, NY 10105 Dear Members of the Board: (August 15th, 2016)

Mill Road Capital Management LLC and its affiliated funds (Mill Road) are pleased to present this proposal (the Proposal) to acquire Skullcandy, Inc. (the Company), which differs from Mill Roads proposal of yesterday in that this Proposal provides the Company with greater security that a closing with Mill Road will occur. Specifically, Mill Road is willing to provide to the Company in escrow its and its affiliates signatures to the Merger Agreement and related documents, as described below. Additionally, we highlight to the Board that our price is higher than the price in the Existing Merger Agreement (as defined below) by 15 cents per share. The terms of our Proposal are as follows:

Selecta Biosciences Inc – Fifth Amended and Restated Investors Rights Agreement (June 8th, 2016)

This Fifth Amended and Restated Investors Rights Agreement dated as of August 26, 2015 (this Agreement), is made by and among: (i) Selecta Biosciences, Inc., a Delaware corporation (the Company); (ii) the holders of the Companys Series A Convertible Preferred Stock, par value $0.0001 per share (the Series A Preferred Stock), the Companys Series B Convertible Preferred Stock, par value $0.0001 per share (the Series B Preferred Stock), the Companys Series C Convertible Preferred Stock, par value $0.0001 per share, (the Series C Preferred Stock), the Companys Series D Convertible Preferred Stock, par value $0.0001 per share (the Series D Preferred Stock), the Companys Series E Convertible Preferred Stock, par value $0.0001 per share, (the Series E Preferred Stock and, collectively with the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock and the Series D Preferred Stock, the Senior Preferred Stock), and the Companys Series SRN Convertible Preferred S

AGREEMENT FOR LEASES Relating to Unit 2, Part Ground Floor and Fourth Floor, 8 Finsbury Circus, London EC2 (May 25th, 2016)
Selecta Biosciences Inc – In Accordance With Instruction 2 to Item 601 of Regulation S-K, Below Is a Schedule Setting Forth Details in Which the Omitted Executed Warrants Differ From the Form of Warrant That Follows: (May 24th, 2016)

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ACT), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

Selecta Biosciences Inc – In Accordance With Instruction 2 to Item 601 of Regulation S-K, Below Is a Schedule Setting Forth Details in Which the Omitted Executed Warrants Differ From the Form of Warrant That Follows: Warrantholder (May 24th, 2016)

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ACT), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.